share_log

JP Morgan Maintains Overweight on Cogent Biosciences, Lowers Price Target to $19

Benzinga ·  Aug 7 14:07  · Ratings

JP Morgan analyst Anupam Rama maintains Cogent Biosciences (NASDAQ:COGT) with a Overweight and lowers the price target from $22 to $19.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment